Disease And Outcome Disparities In Multiple Myeloma (Mm): Exploring The Role Of Race/Ethnicity And Obesity In Cooperative Group Clinical Trials

Background: Race/ethnicity is associated with disparate incidence and outcomes in MM, as seen in population-based studies. Their effect on outcomes has not been reported in prospective studies. Obesity is the most consistently associated modifiable risk factor for MM and is influenced by race/ethnicity but its association with outcomes has not been explored. We analyzed patient-level data from published ECOG-ACRIN/SWOG clinical trials in newly diagnosed MM (NDMM) patients (pts) to explore the interplay of race/ethnicity, obesity and outcomes.Methods: Pooled data from 9 ECOG-ACRIN/SWOG clinical trials (E1A06, E4A03, E1A00, E2A02, E5A93, E9486, S0204, S0232, S9321) in NDMM (1988-2011) were analyzed. Pts were divided by race : White (W), African-American (AA), other (O); race/ethnicity : Hispanic (H), non-Hispanic White (NHW), non-Hispanic AA (NHAA), non-Hispanic other (NHO); and body mass index (BMI) : u003c25, 25-29.9, ≥30. Associations between these and baseline pt/disease characteristics were assessed using chi-square (categorical) and Wilcoxon rank sum (continuous) tests. Survival distributions were estimated with Kaplan-Meier method and compared between groups using log-rank test. Cox proportional hazards regression was used to estimate hazard ratios in univariate and multivariate models. Time to event data was censored at 6 yrs.Results: Pt distribution by race, race/ethnicity and BMI is shown in Table 1. Race : AA were younger than W (median 59 vs 62 yr), had significantly more females (48% vs 40%; p=0.001) and had a smaller proportion of pts ≥70 yr (18% vs 26%; p 10 while 51% of 0, ISS and DS stage III, presence of lytic lesions, Cr ≥2 mg/dL, Ca u003e12 mg/dL, Hb ≤10 g/dL. No significant difference was seen in OS or progression free survival by race, race/ethnicity or BMI (Figure 1).Conclusions: Significant differences exist in demographic and clinical characteristics of NDMM pts by race/ethnicity. Median OS was significantly associated with these characteristics but not with race/ethnicity itself. Observed racial/ethnic disparity in outcomes for MM pts may be overcome by access to comparable therapeutic options as seen in clinical trials. Obesity, while associated with MM incidence, does not seem to influence outcomes.![Figure][1] ![Figure 1][1] Figure 1 Disclosures Ailawadhi: Pharmacyclics: Consultancy; Novartis: Consultancy; Amgen Inc: Consultancy; Takeda Oncology: Consultancy. Stewart: Janssen Pharmaceuticals: Consultancy; Takeda Oncology: Consultancy; Celgene: Consultancy; Bristol Myers Squibb: Consultancy. Hussein: Celgene: Zonder: Takeda: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Pharmacyclics: Other: DSMC membership; Prothena: Consultancy, Honoraria. Barlogie: Mount Sinai Hospital: Employment. [1]: pending:yes